Strategic financing Biohm Technologies recently secured 4.5M in financing, signaling strong investor confidence and potential for accelerated product development, clinical trials, and expanded go-to-market activities that sales teams can leverage to justify increased outreach and expedited partnerships.

Leadership expansion Appointment of Dr. John Deaton as Vice President of Science & Technology, concurrent with new funding, indicates a reinforced R&D focus and credibility that can be used to open conversations with pharma, supplements brands, and contract research organizations seeking advanced microbiome solutions.

Product differentiator Flagship Mycohsa™ probiotic blend is data-powered and validated in clinical trials, enabling sales messaging around unique biofilm breakdown and gut health benefits that differentiate Biohm from bacteria-only competitors and appeal to premium wellness brands.

Private label potential Offerings include comprehensive microbiome gut testing kits as a private label solution for health and wellness brands, presenting a clear channel for B2B partnerships with faster onboarding and co-branding opportunities.

Industry engagement Active presence at SupplySide Connect New Jersey 2025 and Natural Products Expo West 2025, along with AI technology development partnerships, create multiple event-driven sales moments and potential collaborations with retailers, manufacturers, and technology partners.